RAPT Q3 2023 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$34M

Net Income

-$31M

EPS (Diluted)

$-6.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$200M

Total Liabilities

$27M

Stockholders' Equity

$173M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$34M	-$22M	-56.5%
Net Income	-$31M	-$21M	-47.7%